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Abstract
The p38 MAPK pathway plays a key role in regulating the production of proinflammatory cytokines, such as TNFa and IL-1b,
in peripheral inflammatory disorders. There are four major isoforms of p38 MAPK (p38a, b, d, c), with p38a and p38b the
targets of most p38 MAPK inhibitor drugs. Our previous studies demonstrated that the p38a MAPK isoform is an important
contributor to stressor-induced proinflammatory cytokine up-regulation and neurotoxicity in the brain. However, the
potential role of the p38b MAPK isoform in CNS proinflammatory cytokine overproduction and neurotoxicity is poorly
understood. In the current studies, we used primary microglia from wild type (WT) and p38b knockout (KO) mice in co-
culture with WT neurons, and measured proinflammatory cytokines and neuron death after LPS insult. We also measured
neuroinflammatory responses in vivo in WT and p38b KO mice after administration of LPS by intraperitoneal or
intracerebroventricular injection. WT and p38b KO microglia/neuron co-cultures showed similar levels of TNFa and IL-1b
production in response to LPS treatment, and no differences in LPS-induced neurotoxicity. The in vitro results were
confirmed in vivo, where levels of TNFa and IL-1b in the CNS were not significantly different between WT or p38b KO mice
after LPS insult. Our results suggest that, similar to peripheral inflammation, p38a is critical but p38b MAPK is dispensable in
the brain in regards to proinflammatory cytokine production and neurotoxicity induced by LPS inflammatory insult.
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Introduction
Neuroinflammation and overproduction of proinflammatory
cytokines are implicated in the pathological process of chronic
neurodegenerative disorders such as Alzheimer’s disease (AD) (for
recent review see: [1]) and acute trauma such as spinal cord injury
(for recent review see: [2]). One of the most well established
intracellular signal transduction cascades that regulate the
production of proinflammatory cytokines is the p38 mitogen
activated protein kinase (MAPK) family [3,4]. Consisting of four
major isoforms (p38a, b, d, c), these kinases are encoded by
separate genes, expressed in different tissues and cell types, and are
often functionally distinct (for review see: [5]). For example, p38a
is expressed in most tissues and cell types, whereas the other
isoforms are expressed in a more restricted distribution, with p38b
high in brain, p38d in endocrine glands, and p38c in skeletal
muscle [6,7]. The roles of specific p38 isoforms in various
physiological and pathological processes are under active investi-
gation, but available evidence supports the idea that there can be
both functional redundancies among the p38 isoforms as well as
isoform-specific functions.
In terms of inflammatory pathways, the p38a isoform plays a
major role in cytokine up-regulation in both CNS inflammatory
disorders and peripheral inflammatory diseases [8,9]. We previ-
ously showed, using both a pharmacological approach with a
selective small molecule p38a MAPK inhibitor and a genetic
approach with primary microglia that are deficient in p38a, that
this isoform is critical for the production of cytokines from
activated microglia [8]. Moreover, pharmacological inhibition of
p38a MAPK in an AD mouse model decreases brain proin-
flammatory cytokine production, and attenuates synaptic protein
loss [10]. Our more recent study further demonstrated that the
deficiency of microglial p38a MAPK rescues neurons and reduces
synaptic protein loss via suppressing LPS-induced TNFa overpro-
duction [11]. These data demonstrated that microglia p38a
MAPK-mediated cytokine overproduction is critical to inflamma-
tion-induced neurotoxicity. However, the role of p38b MAPK in
CNS proinflammatory cytokine production and neurotoxicity is
poorly understood.
In peripheral inflammatory models, p38b MAPK has been
shown to be expendable, with p38b MAPK deficiency affording
no protection in arthritis models, inflammatory bowel disease, or
LPS-induced TNFa production in the serum [12,13]. On the
other hand, p38b has been reported to be important in protecting
mesangial cells from TNFa toxicity, and appears to be involved in
the cytoprotective effect of carbon monoxide in vitro [14,15,16].
Recent studies demonstrated a role for p38b MAPK during
sympathetic neuron transdifferentiation [17], as well as reducing
sensitivity to pain following spinal cord injury [18], suggesting that
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p38b MAPK may have specific functions in the CNS that are not
seen in the periphery. The goal of the current study was to explore,
in a CNS context, whether p38b MAPK signaling contributes to
LPS-induced proinflammatory cytokine production, as well as
LPS-induced neuronal damage. In agreement with the peripheral
inflammatory models, we found that p38b does not play a role in
LPS-induced neuroinflammation and neurotoxicity.
Materials and Methods
Ethics Statement
All mouse experiments were conducted in accordance with the
principles of animal care and experimentation in the Guide For
the Care and Use of Laboratory Animals. The Institutional
Animal Care and Use Committee of the University of Kentucky
approved the use of animals in this study (protocol #2010-0615).
Reagents
Lipopolysaccharides (LPS) from Salmonella enterica serotype typhi-
murium was obtained from Sigma-Aldrich, St. Louis, MO (Cat.
no. L6143-1MG; EU/MG of LPS is 600,000).
Animals
C57BL/6 mice were obtained from Harlan Laboratories. The
p38b MAPK global KO mice were generated [13] and obtained
from Dr. Stephen J. O’Keefe at Merck Research Laboratories.
Genotyping was performed by Transnetyx, Inc (Cordova, TN).
Primary neuronal culture
Primary neuronal cultures were derived from embryonic day
18, C57BL/6 mice, as previously described [11]. Briefly, cerebral
cortices were dissected and the meninges were removed. Cells
were dissociated by trypsinization for 20–25 min at 37uC and
triturated, followed by passing through a 70 mm nylon mesh cell
strainer. The neurons were plated onto poly-D-lysine-coated 12-
mm glass coverslips at a density of 56104/well in 24 well plates.
Neurons were grown in neurobasal medium (Invitrogen) contain-
ing 2% B27 supplement (Invitrogen), 0.5 mM L-glutamine
(Mediatech), and 100 IU/ml penicillin, 100 mg/ml streptomycin
(Mediatech); no serum or mitosis inhibitors were used. Every 3
days, 50% of the media was replenished with fresh medium. The
purity of the primary neuronal cultures was verified as 93% by
immunocytochemistry for the neuronal marker NeuN, astrocyte
marker GFAP, and microglia marker Iba-1 (data not shown).
Microglia culture
Microglia cultures were prepared as previously described [11].
Briefly, mixed glial cultures (,95% astrocytes, ,5% microglia)
were prepared from the cerebral cortices of 1–3 day old mice. The
tissue was trypsinized as above, and the cells were resuspended in
glia complete medium [a-minimum essential medium (a-MEM;
Mediatech) supplemented with 10% fetal bovine serum (FBS) (US
Characterized FBS; Hyclone; Cat no. SH30071.03), 100 IU/ml
penicillin, 100 mg/ml streptomycin, and 2 mM L-Glutamine].
After 10–14 days in culture, microglia were isolated from the
mixed glial cultures by the shake-off procedure [19]. Specifically,
loosely attached microglia were shaken off in an incubator shaker
at 250 rpm for 2 hr at 37uC, the cell-containing medium was
centrifuged at 1806 g for 3 min, and the cells were seeded onto
12-mm glass coverslips at a density of 26104 in 24 well plates,
unless otherwise specified. Prior to plating the microglia on the
coverslip, three equally spaced 1 mm glass beads (Borosilicate;
Sigma) were attached to the coverslip with paraffin wax. The
microglia cultures were verified to be $99% microglia by
immunocytochemistry. Microglia were incubated for one day
before placing into co-culture with neurons.
Primary microglia/neuron co-culture and cell treatments
After 7 days in culture, neurons on coverslips were co-cultured
with mouse microglia as previously described [20], by placing the
microglia-containing coverslips cell side down into the neuron-
containing wells. In this co-culture system, the microglia and
neurons are in close apposition and share the same neurobasal/
B27 culture media, but are separated by the 1 mm glass beads and
do not have direct cell-cell contact. LPS was resuspended in sterile
0.9% sodium chloride at 100 mg/ml, and was used at a final
concentration of 3 ng/ml for all in vitro experiments.
Neuronal Viability Assay
Neuron viability was assayed by trypan blue exclusion [20].
Briefly, neuron-containing coverslips were incubated with 0.2%
trypan blue in Hanks’ Balanced Salt Solution (HBSS) for 2 min in
37uC incubator and then gently rinsed 3 times with HBSS.
Neurons were viewed under bright field microscopy at 2006 final
magnification. Three to five fields were chosen randomly per
coverslip, and a total of 364 to 592 cells were counted per
coverslip. Trypan blue-positive and negative neurons were
counted per field and the ratio of negative cells to the total cells
was taken as the index of neuronal survival rate.
ELISA assays
After 72 hr in the co-cultures, 20 ml conditioned medium was
harvested for TNFa and IL-1b ELISA assay, using kits from Meso
Scale Discovery (MSD) according to the manufacturer’s instruc-
tions.
In vivo systemic and CNS inflammatory models
Adult mice (3–4 month old, ,50% male and female) were used
for in vivo experiments. To induce a systemic innate immune
response, mice received intraperitoneal (IP) injection of LPS
(1 mg/kg) or sterile saline vehicle in a volume of 100 ml [8]. To
induce a CNS inflammatory response, LPS was delivered by
intracerebroventricular (ICV) injection. Briefly, mice were anes-
thetized with 5% isoflurane prior to stabilizing the head using ear
bars in digital mouse stereotaxic frame (Stoelting Instruments).
Anesthesia was maintained with continuous inhalation of isoflur-
ane (2.5%, 1 liter/min). A midline incision was made in the scalp
to expose the skull. A hole was drilled into the skull over the right
lateral ventricle at the following coordinates: AP=20.5 mm;
ML=21.0 mm. Using a 10 ml Hamilton syringe with a blunt 28
gauge needle, saline vehicle or LPS (25 ng) was injected at the
following coordinates: AP=20.5 mm; ML=21.0 mm;
DV=21.8 mm. The Quintessential Stereotaxic Injector (Stoelt-
ing Instruments) was used to inject 2 ml at a rate of 0.5 ml per min.
After injection, the needle was left in place for 2 min before being
slowly withdrawn. The incision was closed using staples, and the
animal was kept on a heat pad until return of normal activity, at
which point the mouse was returned to the home cage. At select
time points, mice were euthanized with an overdose of sodium
pentobarbital (Vibrac Animal Health, cat. no. NDC-051311-103-
25), and transcardially perfused with ice-cold phosphate buffered
saline (PBS) for 5 min. The brains were rapidly dissected and flash
frozen in liquid nitrogen and stored at 280uC for subsequent
biochemical evaluation.
p38b MAPK in Neuroinflammation and Neuroprotection
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Tissue processing and cytokine measurements
Brain cortex or hippocampus was homogenized using high
shear homogenizer (Omni TH115), in a 1:10 (w/v) of ice-cold
freshly prepared lysis buffer consisting of PBS containing 1 mg/ml
Leupeptin, 1 mM PMSF, and 1 mM EDTA. The brain lysates
were centrifuged at 14,0006 g for 20 min at 4uC in a
microcentrifuge. Fifty microliters of the resulting supernatant
(,100 mg of protein) was loaded per well of the MSD plate, and
IL-1b and TNFa levels determined by MSD ELISA assay.
Cytokine levels were normalized to the total amount of protein in
the sample loaded as determined by BCA Protein Assay (Pierce),
and data expressed as pg/ml. The detection limits of the MSD
assays are 3.4 pg/ml for TNFa and 1.5 pg/ml for IL-1b.
Gene expression
RNA was isolated from dissected neocortical tissues stored at
280uC, or from primary microglia cultures using RNeasy mini-
columns (Qiagen, Cat no. 74104) with on-column DNase treat-
ment (Qiagen, Cat no. 79254) according to the manufacturer’s
protocol. RNA quantity and quality were determined using A260/
A280 readings by NanoDrop (Thermo Scientific). Reverse tran-
scription (RT) was done following the manufacturer’s protocol
using High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Cat no. 4368814). A no template and a no RT control
were conducted to control for contamination. Real-time PCR was
performed using the TaqMan Gene Expression assay kit (Applied
Biosystems, Cat no. 4444964) according to the manufacturer’s
instructions on a ViiATM 7 Real-Time PCR System (Applied
Biosystems). The following TaqMan probes (Applied Biosystems)
were used: MAPK 11 (Mm00440955_m1); MAPK12
(Mm00443518_m1); MAPK13 (Mm00442488_m1); MAPK 14
(Mm00442507_m1); 18S rRNA (Hs99999901_s1). Relative gene
expression was calculated by the 22DDCT method.
Statistics
Statistical analysis was conducted using GraphPad prism
software V.5 (GraphPad Software, La Jolla, CA). Unless otherwise
indicated, values are expressed as mean 6 SEM. Groups of two
were compared by unpaired t-Test. One-way ANOVA followed
by Bonferroni’s multiple comparison test was used for comparisons
among three or more groups. Statistical significance was defined as
p,0.05.
Results
Verification of p38b KO in microglia and brain
As a control for our studies, it was important to confirm the
deletion of p38b MAPK in both the microglia cultures and the
mouse brain tissue, and determine that significant compensatory
changes in the other p38 isoforms were not present. Therefore,
RNA was prepared from primary microglia cultures derived from
WT or p38b KO mice (Figure 1A), and from lysates of WT and
p38b KO mouse cortical tissue (Figure 1B), and the expression
levels of the four p38 MAPK isoforms (p38a, p38b, p38d, p38c)
were determined by qPCR. In both the microglia cultures and the
brain tissue, p38b mRNA was readily measureable in WT mice
but was not detected in the p38b KO mice. The mRNA level of
p38a MAPK is ,10–100 fold higher than that of the other
isoforms in both WT and p38b KO microglia and brain tissue,
and there was no significant difference between the levels of p38a
MAPK in either WT or p38b KO mice. The levels of p38d
mRNA were very low to undetectable in both WT and p38b KO
mice. The expression of p38c mRNA was slightly higher in
microglia cultures from p38b KO mice compared to microglia
from WT mice, but this difference was not seen in the cortical
tissue samples. Altogether, these data verify that, as expected,
p38b is deficient in microglia cultures and brain tissue from the
p38b KO mice.
p38b KO in microglia did not inhibit LPS-induced
cytokine production in microglia/neuron co-culture
As an initial step to determine the effect of microglial p38b
deficiency on LPS-induced proinflammatory cytokine production,
primary microglia from WT or p38b KO mice were co-cultured
with WT primary neurons and treated with either vehicle or LPS
Figure 1. Verification of p38b KO in microglia and brain. Primary
microglia from mouse cortex were prepared as described in Methods
and plated at 16104 cells/well in 48 well plates. Total RNA from
microglia cultures (A) or from mouse cortical tissue (B) derived from WT
(white bars) or p38b KO (black bars) mice was isolated, and the mRNA
levels of different p38 MAPK isoforms were determined by qPCR. In
both the microglia cultures and the brain tissues, p38b mRNA was
readily measureable in WT mice but was not detected in the p38b KO
mice. The p38a MAPK isoform in both microglia and cortex was
expressed at much higher levels than any of the other isoforms, and
there was no significant difference between the levels of p38a in either
WT or p38b KO mice. The levels of p38d mRNA were very low to
undetectable in both WT and p38b KO mice. The expression of p38c
mRNA was slightly higher in microglia cultures from p38b KO mice
compared to microglia from WT mice, but this difference was not seen
in the cortical tissue samples. Results are expressed as fold change
compared to p38b levels, and represent the mean 6 SEM of two
determinations.
doi:10.1371/journal.pone.0056852.g001
p38b MAPK in Neuroinflammation and Neuroprotection
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(3 ng/ml) for 72 hr. LPS induced a highly significant increase in
the production of TNFa, and similar levels of TNFa induction
were seen in WT or p38b KO microglia (Figure 2A). In a similar
fashion, LPS stimulated a ,100-fold increase in IL-1b levels in
both the WT and p38b KO groups, with no differences detected
between these two groups upon LPS challenge (Figure 2B). These
results document that p38b in microglia is not required for LPS-
induced cytokine production.
p38b KO in microglia failed to protect neurons against
LPS-induced neurotoxicity in microglia/neuron co-culture
Previously we found p38a MAPK signaling is important for
activated microglia-induced neuronal death in the microglia/
neuron co-culture, and that p38a MAPK deficiency in microglia
protects against LPS-induced neurotoxicity [11]. However, the
potential contribution of microglial p38b MAPK to LPS-induced
neurotoxicity is not known. To determine if p38b deletion in
microglia can provide similar neuroprotective effects against LPS-
induced neuron damage, we isolated microglia from either WT or
p38b KO mice, placed them in co-culture with WT primary
cortical neurons, and tested whether the absence or presence of
microglia p38b would affect LPS-induced neurotoxicity. Treat-
ment of WT microglia/neuron co-cultures with LPS for 72 hr led
to significant neuronal death, as determined by trypan blue
exclusion assay (Figure 3). In addition, a similar percentage (45%)
of LPS-induced neuronal death was found when neurons were co-
cultured with p38b KO microglia (Figure 3), showing that p38b
MAPK deficiency in microglia does not protect against LPS-
induced neurotoxicity.
p38b KO failed to block CNS proinflammatory cytokine
response to systemic and focal LPS insult in vivo
To test the effect of global p38b deletion on cytokine production
in the brain after inflammatory insult, we administered LPS to
WT or p38b KO mice by two paradigms: systemic insult by IP
injection (Figure 4A), and direct CNS focal insult by ICV injection
(Figure 4B).
To induce systemic inflammation, we administered a single dose
of LPS (1 mg/kg; IP) to WT and p38b KO mice, harvested
cortical tissue at 6 hr after injection, and measured TNFa and IL-
1b levels by ELISA. At the dose of LPS used, TNFa levels were
near the limits of detection of the assay, but the TNFa levels
reached were similar in the WT and p38b KO mice. IL-1b levels
increased significantly after LPS treatment, and no significant
differences in LPS-induced cytokine levels were seen between the
WT and p38b KO mice (Figure 4A).
To determine whether p38b MAPK is important for proin-
flammatory cytokine production induced by a direct CNS focal
inflammation stimulus, LPS was injected into the right lateral
ventricle of WT or p38b KO mice. The peak of the IL-1b
response in the ipsilateral hippocampus following ICV LPS occurs
,6 hr post-injection (data not shown); therefore this time point
was chosen for cytokine analysis. The result showed that the levels
of TNFa and IL-1b increased substantially in both WT and p38b
KO mice administered LPS ICV. In addition, consistent with the
Figure 2. Microglial p38b MAPK deficiency failed to reduce
LPS-induced TNFa and IL-1b production in microglia/neuron
co-culture. Mouse primary cortical neurons at DIV7 (56104/well) were
co-cultured with microglia (26104/well) from WT or p38b KO mice, and
the cytokine levels of TNFa and IL-1b were measured by ELISA after
72 hr exposure to vehicle or LPS (3 ng/ml). LPS induced a significant
increase in TNFa (A) and IL-1b (B) production, and p38b deficiency in
microglia did not reduce the production of TNFa and IL-1b. Data
represent the mean 6 SEM from 2–4 independent experiments.
****p,0.0001 WT-veh vs. WT-LPS; ###p,0.001, ####p,0.0001 KO-
veh vs. KO-LPS.
doi:10.1371/journal.pone.0056852.g002
Figure 3. Microglial p38b MAPK deficiency failed to protect
cortical neurons against LPS-induced neurotoxicity in microg-
lia/neuron co-culture. WT mouse primary cortical neurons were
plated on coverslips at 56104/well, and were co-cultured with microglia
(26104/well) from WT or p38b KO mice. Cells were treated with either
vehicle or LPS (3 ng/ml) for 72 hr, followed by trypan blue exclusion
assay to evaluate neuronal survival. LPS treatment induced significant
neuronal death in WT microglia/WT neuron co-culture. Similar levels of
neuronal death were seen in LPS-treated co-cultures of p38b KO
microglia/WT neurons. Data represent the mean 6 SEM from 2–4
independent experiments. ****p,0.0001 WT-veh vs. WT-LPS;
####p,0.0001 KO-veh vs. KO-LPS.
doi:10.1371/journal.pone.0056852.g003
p38b MAPK in Neuroinflammation and Neuroprotection
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results from systemic IP administration of LPS, no significant
differences in LPS-induced cytokine levels were seen between WT
and p38b KO samples (Figure 4B).
Discussion
In the current study, we used LPS-insulted microglia/neuron
co-culture in vitro and LPS-induced neuroinflammation in in vivo
mouse models (IP and ICV) to test a potential contribution of
p38b MAPK to the production of proinflammatory cytokines and
the survival of cortical neurons. Our results document that p38b
MAPK in the brain is not a critical player in LPS-induced
neuroinflammation and neurotoxicity, since 1) p38b KO in
microglia co-cultured with primary neurons failed to reduce the
cytokine production, 2) p38b deletion in microglia cannot rescue
neurons against LPS toxicity in co-cultures, and 3) no differences
in brain cytokine levels were found between WT and p38b global
KO mice in both LPS IP or ICV models. The findings that the
LPS-induced CNS responses were not compromised in p38b KO
mice support a functionally dispensable role for p38b in LPS-
induced neuroinflammation and neurotoxicity. This is in contrast
to the critical role of microglial p38a in LPS-induced cytokine
production and neuron death in microglia/neuron co-culture
[8,11].
Few studies have examined the role of p38b in CNS disease
models, even though this isoform is expressed at substantial levels
in the brain [21]. In animal models of ischemia, p38a and p38b
levels and activity increased in different cell types and with
different temporal kinetics in the post-ischemic brain. For
example, in transient global ischemia, p38a was induced early
after ischemic insult and was localized mainly to microglia,
whereas p38b induction was delayed and more protracted and was
localized to astrocytes [22]. In a model of transient focal ischemia,
p38b increased early and transiently in neurons, followed by a
later increase in astrocytes [23]. Delayed induction of p38b in
astrocytes has also been reported in mice subjected to kainate-
induced seizures [24], and p38 inhibitor treatment attenuated
kainate-induced hippocampal neuron loss and astrocyte activation
[25]. Down-regulation of p38b, but not p38a, was also found to
reduce sensitivity to pain following spinal cord injury [18]. In
contrast to the reports above that suggest a potentially detrimental
role of p38b in certain CNS disease models, other studies suggest
that p38b may have specific beneficial roles in the CNS. For
example, a recent study showed that p38b overexpression provides
protection against H2O2-induced apoptosis in an astrocyte cell line
by inducing a small heat shock protein and inhibiting caspase-3
activation [26]. The p38b isoform was also reported to play an
important role in the process by which postmitotic sympathetic
noradrenergic neurons change to cholinergic neurons, and this
neurotransmitter switch mechanism was impaired in neurons from
p38b KO mice [17]. Taken together, these previous reports
suggest that p38a and p38b may play distinct roles in different
CNS disease models, and that their redundant or specific functions
may depend on the spatial and temporal features of their
activation in response to specific stressors.
The results reported here that p38b does not play a major role
in CNS inflammation in response to LPS insult are consistent with
previous studies examining the role of p38b in peripheral
inflammation models. For example, LPS-induced proinflamma-
tory cytokine production in macrophages and plasma was found to
be similar in WT and p38b KO mice, and the p38b KO mice also
responded normally in animal models of rheumatoid arthritis and
inflammatory bowel disease [12,13]. These data demonstrated
that p38b was not required for these peripheral inflammatory
responses. Combined with our findings reported here, the
available evidence shows that the p38b isoform does not play a
key role in either peripheral or CNS proinflammatory cytokine
responses or the resultant neurotoxicity induced by LPS insult.
Figure 4. Proinflammatory cytokine levels in WT and p38b KO
mouse brain in response to LPS insult. CNS inflammatory
responses were induced in WT (white bars) or p38b KO (black bars)
mice upon either systemic insult by LPS IP injection (A) or direct CNS
focal insult by LPS ICV injection (B). In the systemic insult paradigm, WT
mice and p38b KO mice received IP injection of saline vehicle or LPS
(1 mg/kg). Brain samples were harvested at 6 hr post-injection, and the
levels of TNFa and IL-1b were determined by ELISA (A). At this dose of
LPS, the levels of TNFa in the brain were near the level of detection of
the ELISA assay, whereas the IL-1b levels showed a significant increase
upon LPS insult. The profile of cytokine response to LPS stimulus in
p38b KO mice was very similar to the response in WT mice. In the direct
CNS focal insult paradigm, saline vehicle or LPS (25 ng) was injected
into the right lateral ventricle of WT and p38b KO mice. Brain samples
were harvested 6 hr post-injection, and the levels of TNFa and IL-1b
were determined by ELISA (B). Both TNFa and IL-1b were substantially
increased in the brain samples from WT mice upon LPS treatment, and
the p38b KO mice showed a similar induction of these proinflammatory
cytokines. Results represent the mean6 SEM. Cytokine levels in vehicle-
treated mice (gray bars) represent data from both WT and p38b KO
mice. n = 6–8 per group for panels A; n = 7–8 per group for panels B.
**p,0.01, ***p,0.001 vehicle vs. WT-LPS; ##p,0.01, ###p,0.001
vehicle vs. KO-LPS. N.D. = not detected.
doi:10.1371/journal.pone.0056852.g004
p38b MAPK in Neuroinflammation and Neuroprotection
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Taken together with our previous studies documenting the critical
role of p38a MAPK in mediating LPS-induced CNS proinflam-
matory cytokine production and neuron survival [8,11], these
results suggest that p38a and not p38b is the key p38 isoform
involved in peripheral and central inflammatory responses. These
findings also raise the obvious corollary that development of p38
inhibitors to target CNS inflammatory diseases may not need to
consider retention of p38b inhibitory activity, but should instead
focus on selective targeting of the p38a MAPK isoform as a
potential therapeutic strategy.
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